The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu
Trial record 1 of 1 for:    VX-880
Previous Study | Return to List | Next Study

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04786262
Recruitment Status : Recruiting
First Posted : March 8, 2021
Last Update Posted : October 31, 2023
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated

Brief Summary:
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Impaired Hypoglycemic Awareness Severe Hypoglycemia Biological: VX-880 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 17 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Actual Study Start Date : March 29, 2021
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : January 2028

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: VX-880 Biological: VX-880
Infused into the hepatic portal vein.
Other Name: Formerly known as STx-02

Primary Outcome Measures :
  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: From VX-880 infusion to end of study (up to 5 years) ]
  2. Proportion of Participants Free of Severe Hypoglycemic Events With Either a Glycosylated Hemoglobin (HbA1c) <7.0% or a ≥ 1% Reduction in HbA1c From Baseline [ Time Frame: At 1 year after VX-880 infusion ]

Secondary Outcome Measures :
  1. Proportion of Participants who are Insulin Independent [ Time Frame: At 1 year after VX-880 infusion ]
  2. Changes in Stimulated C-peptide [ Time Frame: At 1 year after VX-880 infusion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Clinical history of T1D with > 5 years of duration
  • At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment
  • Stable diabetic treatment
  • Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study

Key Exclusion Criteria:

  • Prior islet cell transplant, organ transplant, or cell therapy

Other protocol defined Inclusion/Exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04786262

Layout table for location contacts
Contact: Medical Information 617-341-6777

Show Show 22 study locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Layout table for additonal information
Responsible Party: Vertex Pharmaceuticals Incorporated Identifier: NCT04786262    
Other Study ID Numbers: VX20-880-101
2022-002292-11 ( EudraCT Number )
First Posted: March 8, 2021    Key Record Dates
Last Update Posted: October 31, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Details on Vertex data sharing criteria and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases